Finerenone for IgA vasculitis with mild proteinuria in children
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests if the drug finerenone can help children with IgA vasculitis (HSP nephritis) who have mild protein in their urine. It aims to protect kidney function without using stronger medications like steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 18 years old.
- You have been diagnosed with IgA vasculitis affecting the kidneys (HSP nephritis).
- You have mild protein in your urine, measured as 300 to 1000 mg per day (or equivalent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
This trial tests whether a new medicine called finerenone can help people with IgA nephropathy, a kidney disease. You may be able to join if you are already on blood pressure medications, your kidney function is at a certain level, and you haven't needed immune-suppressing drugs recently.
This trial studies how safely finerenone works over 18 months in children and young adults with chronic kidney disease who also take an ACE inhibitor or ARB. It aims to better understand long-term side effects when used together with standard kidney blood-pressure medicines.
Hear when a new Henoch Schönlein Purpura Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.